Pfizer (PFE) Plans Price Increases on About 80 Medicines Despite Broader Pricing Deals

Core Insights - Pfizer Inc. is planning to raise prices on approximately 350 medicines starting January 1, despite broader pricing agreements with the Trump administration aimed at lowering costs for certain treatments [2][4] - The company announced the largest number of list price hikes, affecting around 80 medicines, including notable drugs like Ibrance, Nurtec, and Paxlovid [3][4] - Most price increases are under 10%, with a notable 15% increase for the COVID vaccine Comirnaty, while some lower-priced hospital drugs are seeing increases of more than four times [4] Pricing Strategy - Pfizer's average list price adjustments for innovative medicines and vaccines for 2026 are designed to remain below the overall rate of inflation [4] - The planned price increases for 2026 are higher than the previous year, with over 250 drugs outlined for hikes last year, and this year's median increase is around 4% [5] Company Overview - Pfizer Inc. is a research-driven biopharmaceutical company with global operations, focusing on the discovery, development, manufacturing, and marketing of medicines and vaccines across various therapeutic areas [5]